Teva Wins Appeal That Upholds Three Patents for Migraine Drug

Teva Pharmaceutical Industries Ltd. won a U.S. appeals court ruling that upheld three patents on its Ajovy migraine drug, though six other patents on the treatment were ruled invalid.

Eli Lilly & Co., which makes the competing drug Emgality, had argued that all nine patents were invalid. The patents are part of an infringement suit Teva filed against Lilly in 2018 in federal court in Boston, right after Emgality won U.S. regulatory approval.

The patents relate to antibodies that target calcitonin gene-related peptide, a molecule linked to migraines. Teva had argued that the antibodies were discovered after “years of ...